BETHESDA, Md. - The FDA's Oncologic Drugs Advisory Committee voted 10-5 in favor of approving Celgene Corp.'s Revlimid (lenalidomide) for myelodysplastic syndromes (MDS) in transfusion-dependent patients with a 5q-deletion chromosomal abnormality. (BioWorld Today)